Natera, Inc. (NASDAQ:NTRA) is Tri Locum Partners LP’s 4th Largest Position

Tri Locum Partners LP trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 36.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 202,646 shares of the medical research company’s stock after selling 114,793 shares during the quarter. Natera accounts for approximately 6.6% of Tri Locum Partners LP’s holdings, making the stock its 4th biggest holding. Tri Locum Partners LP’s holdings in Natera were worth $32,079,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Natera in the 3rd quarter valued at about $385,000. Everence Capital Management Inc. acquired a new stake in Natera in the fourth quarter valued at approximately $573,000. Smartleaf Asset Management LLC grew its holdings in Natera by 50.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after purchasing an additional 220 shares during the last quarter. SeaBridge Investment Advisors LLC purchased a new position in Natera in the fourth quarter worth $2,894,000. Finally, SYM FINANCIAL Corp acquired a new position in shares of Natera during the fourth quarter worth $256,000. Institutional investors own 99.90% of the company’s stock.

Natera Trading Down 0.4 %

NASDAQ NTRA opened at $153.79 on Friday. Natera, Inc. has a 1 year low of $90.88 and a 1 year high of $183.00. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market capitalization of $20.79 billion, a PE ratio of -87.38 and a beta of 1.80. The company has a fifty day moving average of $147.95 and a 200 day moving average of $153.52.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million during the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 1,442 shares of the company’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $161.87, for a total value of $233,416.54. Following the completion of the transaction, the chief financial officer now owns 108,032 shares in the company, valued at approximately $17,487,139.84. This represents a 1.32 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 1,664 shares of the stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $145.55, for a total transaction of $242,195.20. Following the sale, the chief executive officer now directly owns 198,365 shares in the company, valued at approximately $28,872,025.75. The trade was a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 198,743 shares of company stock valued at $30,558,447. 7.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, January 28th. Morgan Stanley raised their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Barclays cut their price objective on shares of Natera from $200.00 to $160.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. Royal Bank of Canada started coverage on shares of Natera in a research report on Thursday, March 13th. They issued an “outperform” rating and a $251.00 price objective for the company. Finally, Robert W. Baird boosted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $175.76.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.